Correlation study between programmed death receptor ligand (PD-L1) expression and venous thromboembolism (VTE) in patients with non-small cell lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300075385

Enrollment

Unknown

Registered

2023-09-04

Start date

2023-09-04

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

venous thromboembolism

Interventions

Retrospective cohort of PD-L1 expression positive group:NA

Retrospective cohort of PD-L1 expression negative group:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with lung cancer admitted to Beijing Hospital, which diagnosed with NSCLC by histopathology or cell wax mass, including lung adenocarcinoma and squamous cell carcinoma; 2. PD-L1 immunohistochemical test was performed; 3. Elder than 18 years; 4. Subject informed consent has been signed

Exclusion criteria

Exclusion criteria: NSCLC patients who did not undergo PD-L1 immunohistochemical testing; Warfarin, low molecular weight heparin and other anticoagulant drugs for various reasons; Patients with a history of VTE before diagnosis of lung cancer

Design outcomes

Primary

Measure	Time frame
expression of PD-L1;venous thromboembolism;	—

Secondary

Measure	Time frame
All-Cause Mortality;	—

Countries

China

Contacts

Public ContactXu Xiaomao

Beijing Hospital

xuxiaomao@163.com+86 135 8191 5081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026